BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
59.00
+1.65 (2.88%)
At close: Jun 26, 2026, 4:00 PM EDT
58.60
-0.40 (-0.68%)
After-hours: Jun 26, 2026, 7:59 PM EDT
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for BioMarin Pharmaceutical stock have an average target of 87.26, with a low estimate of 50 and a high estimate of 120. The average target predicts an increase of 47.90% from the current stock price of 59.00.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock from 26 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 14 | 14 | 14 | 14 |
| Buy | 4 | 4 | 4 | 5 | 6 | 6 |
| Hold | 6 | 5 | 5 | 5 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 23 | 24 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Guggenheim No rating | Guggenheim | Buy Maintains $86 | Buy | Maintains | $86 | +45.76% | Jun 3, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $80 | Buy | Reiterates | $80 | +35.59% | May 29, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $68 | Hold | Maintains | $68 | +15.25% | May 24, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $116 → $111 | Buy | Maintains | $116 → $111 | +88.14% | May 22, 2026 |
| Raymond James | Raymond James | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 22, 2026 |
Financial Forecast
Revenue This Year
3.90B
from 3.22B
Increased by 21.00%
Revenue Next Year
4.46B
from 3.90B
Increased by 14.50%
EPS This Year
4.94
from 3.15
Increased by 56.73%
EPS Next Year
6.46
from 4.94
Increased by 30.92%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.4B | 5.3B | |
| Avg | 3.9B | 4.5B | |
| Low | 3.8B | 4.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.8% | 35.3% | |
| Avg | 21.0% | 14.5% | |
| Low | 19.0% | 8.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.01 | 7.58 | |
| Avg | 4.94 | 6.46 | |
| Low | 4.86 | 4.52 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 59.0% | 53.5% | |
| Avg | 56.7% | 30.9% | |
| Low | 54.3% | -8.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.